Aesthetic Management Partners has introduced Cellenis® Exo-ME™, an autologous, point-of-care system that processes a patient’s own blood into a concentrated preparation of extracellular vesicles (EVs), including exosomes, and bioactive proteins.
Get the latest in Medical Aesthetics in our weekly ValuraNova Pulse. Sign up now.
The technology extends the company’s Cellenis® PRP portfolio, using blood-derived components to create a personalized preparation for aesthetic skin and scalp protocols. It is also positioned for use in hair and scalp treatments.
Exo-ME™ is designed to concentrate EVs and bioactive proteins already present in the patient’s blood, providing practitioners with an autologous option within the growing skin-booster market.
The launch builds on Cellenis’ established blood-based platform while expanding its applications into personalized skin quality and hair protocols.
Read the full story here.
